Literature DB >> 32492356

How Is Quality of Life Assessed in People With Dementia? A Systematic Literature Review and a Primer for Speech-Language Pathologists.

Sabine Heuer1, Rebecca Willer1.   

Abstract

Purpose The purpose of this study was to determine how quality of life (QoL) is measured in people with dementia involved in interventions designed to improve well-being and to explore how those measures align with principles of person-centered care. Method A systematic literature review was conducted utilizing PsychInfo, CINAHL, and PubMed and combinations of the search terms: "dementia," "outcome measure," "creative engagement," "creative intervention," "TimeSlips," "art," "quality of life," and "well-being." The search was limited to studies published in peer-reviewed journals that reported outcomes for people with dementia in response to a creative intervention. Results Across the 24 reviewed studies, 30 different outcome measures were reported including eight self-reported, nine observational, and 13 proxy-reported measures. Self-report of QoL was elicited 16 times, observational measures were reported 17 times, and proxy-reported measures were used 28 times. All measures were used with participants across the dementia severity spectrum. Conclusion Current clinical practice of QoL evaluation does not align well with person-centered care principles of self-determination based on the low proportion of self-report. The previously reported limitations of proxy-report have been in part confirmed with this study. Implications of the findings for speech-language pathologists are discussed.

Entities:  

Mesh:

Year:  2020        PMID: 32492356     DOI: 10.1044/2020_AJSLP-19-00169

Source DB:  PubMed          Journal:  Am J Speech Lang Pathol        ISSN: 1058-0360            Impact factor:   2.408


  1 in total

1.  Psychometric Properties of the ICECAP-O Quality of Life Measurement Tool When Self-reported by Community-dwelling Older People With Mild and Moderate Dementia.

Authors:  Samuel R Nyman; Chloe Casey; Remco Polman
Journal:  Alzheimer Dis Assoc Disord       Date:  2021 Oct-Dec 01       Impact factor: 2.357

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.